. For patients receiving palliative oncology, we compared characteristics of completers and non-completers of chemotherapy using c 2 tests and multiple logistic regression models with correction for cluster sampling. For variables with missing data we imputed values using multiple imputation by chained equations. Results Of 16 264 patients participating in the NOGCA in England, 2313 received palliative chemotherapy treatment. Female patients or patients of older age were less likely to receive treatment. Overall, only 39.7% completed their treatment. Factors associated with treatment completion were low performance status, high age and high level of deprivation. In our study, treatment completion was not related with site of cancer, pre-treatment stage, sex, comorbidities or histology. Conclusion Completion rates of palliative chemotherapy in patients with oesophago-gastric cancer are low. The low completion rates may reflect the complex medical decision making for this group of patients and the need to balance survival benefits, toxicity of treatment, patients' preferences and patients' quality of life. Patients unlikely to complete chemotherapy may be more appropriately managed on a palliative supportive care pathway with symptom control.
Introduction The status of the circumferential resection margin (CRM) in oesophageal cancer has been suggested as a prognostic factor but the reports are conflicting. Also, there are two methods of defining positive CRMdwithin 1 mm (Royal College of Pathologists, RCPath UK) 1 and 0 mm (College of American Pathologists, CAP). 2 Methods A systematic review was carried out using a pre-defined protocol and papers that met the inclusion criteria were selected. Data extracted from those with required adjusted HR for metaanalysis using STATA-11 statistical software. Assessments were made for heterogeneity, publication bias, small study effects and sensitivity analysis for influence. Results Fourteen cohort studies 3e16 were systematically reviewed but nine 4 5 9 10e15 meta-analysed. Abstract PWE-023 table 1 shows the results of the pooled overall and CRM criteria sub-group estimates. There was significant heterogeneity between the studies (p value<0.001 and I 2 value of 74.8%). There was evidence of publication bias and small study effects (Egger 's test p value 0.029). None of the studies had undue influence.
Abstract PWE-023 Conclusion This meta-analysis provides evidence that the CRM status in oesophageal carcinoma has prognostic significance. This significance is present irrespective of the criteria used for defining the margin but the estimate for the 0 mm CAP criterion is much higher than those of the within 1 mm RCPath criterion. The overall HR of 1.58 (95% CI 1.40 to 1.79) suggests patients with positive CRM have 60% more risk of death compared to patients with a negative margin. The significant heterogeneity and publication bias are limitations to the study and the former in particular requires further analysis.
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